Bray Christina Elaine 4

What Happened Christina Elaine Bray, a director of BioLargo, Inc. (BLGO), was granted an option award covering 115,741 shares on 2026-03-31. The option was issued as payment for $18,750 in board fees under the company’s 2024 Equity Incentive Plan. This is a derivative grant (an option award), not an open-market purchase or a sale.

Key Details

• Transaction date: 2026-03-31; filing date (Form 4): 2026-04-01 (appears timely).
• Transaction type: Award/Grant (derivative option).
• Shares/options granted: 115,741.
• Consideration: issued in lieu of $18,750 in fees owed to the director.
• Footnote: the number of option shares equals the fees due divided by the option’s exercise price. This implies an approximate exercise price of $18,750 / 115,741 ≈ $0.162 per share (exercise price not explicitly listed).
• Shares owned after transaction: not specified in the filing.
• No immediate sale of shares reported — these are option rights, not exercised shares.

Context This is a compensation award to a board member, converting compensation owed into an equity-based option under the company plan. Such awards are routine board compensation and do not by themselves indicate buying or selling sentiment. Because this is an option grant (derivative), it does not create immediately transferable common shares unless and until the option is exercised and any vesting or other plan conditions are satisfied.